Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
about
Biologic imaging of head and neck cancer: the present and the futureThe role of neck dissection in squamous cell carcinoma of the head and neck.Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancersReliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancerFeasibility of tomotherapy-based image-guided radiotherapy for locally advanced oropharyngeal cancerFDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CTOpportunities and challenges facing biomarker development for personalized head and neck cancer treatment.Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective studyLong-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies.Effect of postradiotherapy neck dissection on nonregional disease sites.The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy.Current concepts of surveillance and its significance in head and neck cancer.Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients.Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinomaViable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcomeEarly detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck.Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer: A Cross-Sectional Analysis in Single Institute.(18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy.Multimodality functional imaging using DW-MRI and 18F-FDG-PET/CT during radiation therapy for human papillomavirus negative head and neck squamous cell carcinoma: Meixoeiro Hospital of Vigo Experience.Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy.Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.Role of positron emission tomography--computed tomography in head and neck cancer.The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients.Newer imaging techniques in head and neck cancer.Assessment of treatment response after chemoradiation of head and neck cancer.The role of neck dissection after radical chemoradiation for locally advanced head and neck cancer: should we move back?.Current advances in diagnosis and surgical treatment of lymph node metastasis in head and neck cancer.[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapyObservation versus neck dissection for positron-emission tomography-negative lymphadenopathy after chemoradiotherapy.Emerging biomarkers in head and neck cancer in the era of genomics.(18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications.AHNS Series--Do you know your guidelines? Guideline recommended follow-up and surveillance of head and neck cancer survivors.Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma.Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.
P2860
Q27023296-7DA067B6-A1F8-4A16-8474-CE81DDBD59F8Q30366869-EB08E4BA-16DB-4BA9-A12E-7D85E7B077A8Q33793870-B6945C8C-E12D-4CE6-9FBB-8B1637617A68Q34153043-0516E345-E2FF-4A04-A3B8-85D29C2B5E86Q34156288-5971AB8E-9EEE-4A7A-A90A-CEC00951D906Q34653643-3B2EF277-D5C7-4C2E-A36E-22D00E82F0C1Q35208087-972265B3-DD81-4519-BDB5-965082CB5C1AQ35591793-A38F49DA-4E65-490B-9796-D965A9A00C3AQ35673572-8FED75F6-36DD-4EF7-B5B0-2A4DD3FBFCBFQ35925534-819E7C2A-5F7A-4312-983F-4D0FD4F2565FQ36060737-E08C2554-1BAA-44AA-A940-EDC700D07093Q36197811-C61A6375-4635-4E95-82E1-8E1D1E1D7DAAQ36326540-7A6FFBCA-7A7B-4EE4-B077-D4B395BB588FQ36407111-F3270E73-9F49-4639-93C6-2A2655ECFC26Q36593688-906C9B12-E79F-4589-9A19-9BAC135EEEEEQ36993641-5FD3BCD2-9F97-4609-85A4-8EACEF454152Q37023751-154C3B4B-7BD0-417F-9813-2A307F0ECE7DQ37170012-4EC09C78-EDA0-4ED4-BCD4-CB48213757DFQ37247189-4BB193CD-C9F3-402E-8475-C6B8CD88CE83Q37314625-EF9CB176-CA54-4C74-B96A-47CF1FBD1C09Q37328698-C7902D65-EE8A-45A8-B7D5-58960EDE601DQ37385263-8EDFDFAF-BE7E-44F9-BDEE-C0E0A65C6AC7Q37439607-6358015E-AEB8-48BF-B31C-A289A577428AQ37590957-592AD3C5-E523-43AD-992A-F8456E99817BQ37781147-6A57EFDE-7E23-4C81-AF9C-E69538B98157Q37919750-91F14526-F756-4813-8A57-0469CC7E4ABEQ37921817-74553CB2-FAC6-4890-AE4B-5CB5CFC94F7FQ37949986-671F35DE-E351-4741-BB8D-1321FF821CDFQ38000079-2D15A1A2-7015-43F9-9C29-C1B572F1C2B7Q38038842-046CF06F-C7E8-4EFB-8F61-AAAA8ECFDA87Q38072336-1631FAFD-013E-47D8-9E42-BD50445FF766Q38073089-0C1496A0-8535-4B7E-9F56-F59645C19452Q38074160-8AC5E18F-A35B-4336-BC1A-71907BA2218FQ38077874-9212F5AB-B0C5-4703-8D3D-F8736EC0F4B4Q38151625-ED8B0357-F019-42E2-8099-BAD17BA72DF9Q38268896-449DD7F1-08D0-485B-A93C-F0B61BF2AF74Q38410245-CF87BC6A-55F5-49C4-8C16-FAF4A914603CQ38444526-EBBF629C-E6EB-4AE3-8B17-B072EEAE107FQ38445194-87DBC72B-7C0D-405C-BBE9-5CA18EA3E1CFQ38617866-EB95C172-C963-4268-A007-74A8287AA6B8
P2860
Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer.
@en
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer.
@nl
type
label
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer.
@en
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer.
@nl
prefLabel
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer.
@en
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer.
@nl
P2093
P1476
Clinical utility of 18F-FDG PE ...... advanced head and neck cancer
@en
P2093
David G Pfister
Dennis H Kraus
Diane Carlson
Heiko Schöder
Matthew Fury
Nancy Y Lee
Seng Chuan Ong
Snehal G Patel
Steven M Larson
P304
P356
10.2967/JNUMED.107.044792
P407
P50
P577
2008-03-14T00:00:00Z